 SALT LAKE CITY, Jan. 08, 2021 GLOBE NEWSWIRE -- Myriad Genetics, Inc. NASDAQ: MYGN, a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula niraparib. myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. 